128
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain

ORCID Icon, ORCID Icon, , , ORCID Icon &
Pages 245-258 | Published online: 25 Jan 2022

References

  • GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30293-X
  • Soriano JB, Alfageme I, Miravitlles M, et al. Prevalence and determinants of COPD in Spain: EPISCAN II. Arch Bronconeumol. 2021;57(1):61–69. doi:10.1016/j.arbres.2020.07.024
  • Soler-Cataluna JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.040527
  • Halpin DM, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017;12:2891–2908. doi:10.2147/COPD.S139470
  • Alcázar Navarrete B, Ancochea Bermúdez J, García-Río F, et al. Patients with Chronic Obstructive Pulmonary Disease exacerbations: recommendations for diagnosis, treatment and care. Arch Bronconeumol. 2019;55(9):478–487. doi:10.1016/j.arbres.2019.02.020
  • Global Initiative for Chronic Obstructive Lung Disease [GOLD]. Global strategy for the diagnosis, management and prevention of Chronic Obstructive Lung Disease (2019 Report); 2019. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed July 20, 2021.
  • Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47(2):625–637. doi:10.1183/13993003.01170-2015
  • Gazzotti MR, Roco CM, Pradella CO, et al. Frequency of osteoporosis and vertebral fractures in Chronic Obstructive Pulmonary Disease (COPD) patients. Arch Bronconeumol. 2019;55(5):252–257. doi:10.1016/j.arbres.2018.10.010
  • Miravitlles M, Auladell-Rispau A, Monteagudo M, et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev. 2021;30(160):210075. doi:10.1183/16000617.0075-2021
  • Miravitlles M, Calle M, Molina J, et al. Spanish COPD guidelines (GesEPOC) 2021: updated Pharmacological treatment of stable COPD. Arch Bronconeumol. 2022;58(1):69-81. doi:10.1016/j.arbr.2021.03.014
  • Miravitlles M, Barrecheguren M, Román-Rodríguez M. Frequency and characteristics of different clinical phenotypes of chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2015;19(8):992–998. doi:10.5588/ijtld.15.0021
  • Izquierdo JL, Morena D, González Y, et al. Clinical management of COPD in a real-world setting. A big data analysis. Arch Bronconeumol. 2021;57(2):94–100. doi:10.1016/j.arbres.2019.12.025
  • Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J. 2020;55(6):2000351. doi:10.1183/13993003.00351-2020
  • Monteagudo M, Nuñez A, Solntseva I, et al. Treatment pathways before and after triple therapy in COPD: a population-based study in primary care in Spain. Arch Bronconeumol. 2021;57(3):205–213. doi:10.1016/j.arbres.2020.07.032
  • Instituto Nacional de Estadística (INE), Madrid, Spain. Available from: https://www.ine.es/CDINEbase/consultar.do?mes=&operacion=Cifras+de+Poblaci%F3n&id_oper=Ir. Accessed January 18, 2022.
  • Miravitlles M, Monteagudo M, Solntseva I, Alcázar B. Blood eosinophil counts and their variability and risk of exacerbations in COPD: a population-based study. Arch Bronconeumol. 2021;57(1):13–20. doi:10.1016/j.arbres.2019.12.015
  • Soler-Cataluña JJ, Martínez-García M, Sánchez Sánchez L, Perpiñá Tordera M, Román Sánchez P. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med. 2009;103(5):692–699. doi:10.1016/j.rmed.2008.12.005
  • Divo MJ, Casanova C, Marin JM, et al. COPD comorbidities network. Eur Respir J. 2015;46(3):640–650. doi:10.1183/09031936.00171614
  • Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish guidelines for management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017 pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324–335. doi:10.1016/j.arbres.2017.03.018
  • Tsiligianni I, Kampouraki M, Ierodiakonou D, Poulonirakis I, Papadokostakis P. COPD patients’ characteristics, usual care, and adherence to guidelines: the Greek UNLOCK study. Int J Chron Obstruct Pulmon Dis. 2019;14:547–556. doi:10.2147/COPD.S185362
  • Casas A, Montes de Oca M, Menezes A, et al. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. Int J Chron Obstruct Pulmon Dis. 2018;13:1545–1556. doi:10.2147/COPD.S154097
  • Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904. doi:10.2147/COPD.S62750
  • Román-Rodríguez M, van Boven JFM, Vargas F, et al. Factors associated with inhaled corticosteroids prescription in primary care patients with COPD: a cross-sectional study in the Balearic Islands (Spain). Eur J Gen Pract. 2016;22(4):232–239. doi:10.1080/13814788.2016.1212011
  • Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of Chronic Obstructive Pulmonary Disease. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69. doi:10.1164/rccm.202003-0625ST
  • Avdeev S, Aisanov Z, Arkhipov V, et al. Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms. Int J Chron Obstruct Pulmon Dis. 2019;14:1267–1280. doi:10.2147/COPD.S207775
  • Miravitlles M, Andreu I, Romero Y, Sitjar S, Altés A, Anton E. Difficulties in differential diagnosis of COPD and asthma in primary care. Br J Gen Pract. 2012;62(595):e68–e75. doi:10.3399/bjgp12X625111
  • Cole JN, Mathur RA, Hull SA. Reducing the use of inhaled corticosteroids in mild-moderate COPD: an observational study in east London. NPJ Prim Care Respir Med. 2020;30(1):34. doi:10.1038/s41533-020-00191-y
  • Erro Iribarren M, Alonso Pérez T, Soriano JB, Ancochea Bermúdez J. Adjusting the Level of intervention in patients with Chronic Obstructive Pulmonary Disease according to the risk stratification proposed by the Spanish COPD guidelines (GesEPOC) version 2017. Arch Bronconeumol. 2020;56(3):183–185. doi:10.1016/j.arbres.2019.09.016
  • Monteagudo M, Barrecheguren M, Solntseva I, et al. Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD. NPJ Prim Care Respir Med. 2021;31(1):16. doi:10.1038/s41533-021-00227-x
  • Bahremand T, Etminan M, Roshan-Moniri N, De Vera MA, Tavakoli H, Are SM. COPD prescription patterns aligned with guidelines? Evidence from a Canadian population-based study. Int J Chron Obstruct Pulmon Dis. 2021;16:751–759.
  • Asensio VJ, Tomás A, Iglesias A, et al. for CHACOS study group. Eosinophilic COPD patients display a distinctive serum miRNA profile from asthma and non-eosinophilic COPD. Arch Bronconeumol. 2020;56(4):234–241. doi:10.1016/j.arbres.2019.09.020
  • Harries TH, Rowland V, Corrigan CJ, et al. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir Res. 2020;21(1):3.
  • Brouwer HJ, Bindels PJE, Weert HC. Data quality improvement in general practice. Fam Pract. 2006;23(5):529–536. doi:10.1093/fampra/cml040